{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:47:57Z","timestamp":1793047677964,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eplepsyres.2024.107286","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T04:01:13Z","timestamp":1704427273000},"page":"107286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Neural hyperexcitability in Angelman syndrome: Genetic factors and pharmacologic treatment approaches"],"prefix":"10.1016","volume":"200","author":[{"given":"Paul J.","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2024.107286_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","article-title":"Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells","volume":"30","author":"Adhikari","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng0997-75","article-title":"Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons","volume":"17","author":"Albrecht","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1469-8749.1965.tb07844.x","article-title":"Puppet\u2019 children a report on three cases","volume":"7","author":"Angelman","year":"1965","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2022.826679","article-title":"Paradoxical hyperexcitability in disorders of neurodevelopment","volume":"15","author":"Antoine","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib5","first-page":"1","article-title":"Therapeutic approach to neurological manifestations of Angelman syndrome","volume":"10","author":"Ascoli","year":"2022","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2015.236","article-title":"Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain","volume":"24","author":"Bailus","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/YPG.0000000000000218","article-title":"Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series","volume":"29","author":"Balaj","year":"2019","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib8","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/WNL.0000000000011409","article-title":"The STARS phase 2 study: a randomized controlled trial of gaboxadol in angelman syndrome","volume":"96","author":"Bird","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/phar.1686","article-title":"Management of sleep disorders in children with neurodevelopmental disorders: a review","volume":"36","author":"Blackmer","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41598-017-08825-x","article-title":"Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice","volume":"7","author":"Born","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0345-20.2020","article-title":"Early developmental eeg and seizure phenotypes in a full gene deletion of ubiquitin protein ligase e3a rat model of angelman syndrome","volume":"8","author":"Born","year":"2021","journal-title":"eNeuro"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.pharep.2014.03.009","article-title":"Antiarrhythmic drugs and epilepsy","volume":"66","author":"Borowicz","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib13","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1523\/JNEUROSCI.4307-04.2005","article-title":"Locus ceruleus activation suppresses feedforward interneurons and reduces \u03b2-\u03b3 electroencephalogram frequencies while it enhances \u03b8 frequencies in rat dentate gyrus","volume":"25","author":"Brown","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jpi.12697","article-title":"Angelman syndrome and melatonin: what can they teach us about sleep regulation","volume":"69","author":"Buonfiglio","year":"2020","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.omtn.2022.04.009","article-title":"AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndrome","volume":"28","author":"Campbell","year":"2022","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2021.08.007","article-title":"Clinical characterization of epilepsy in children with angelman syndrome","volume":"124","author":"Cassater","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib17","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/WNR.0000000000001366","article-title":"Citalopram reduces glutamatergic synaptic transmission in the auditory cortex via activation of 5-HT1A receptors","volume":"30","author":"Cervantes-Ram\u00edrez","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/neu.480050605","article-title":"Pontine neurons in the dorso-lateral","volume":"5","author":"Chu","year":"1974","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2017.10.016","article-title":"Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model","volume":"110","author":"Chung","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2016.08.002","article-title":"Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model","volume":"96","author":"Ciarlone","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2016.12.009","article-title":"Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model","volume":"116","author":"Ciarlone","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.nbd.2005.04.003","article-title":"Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman syndrome","volume":"20","author":"Colas","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib23","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.cub.2021.02.049","article-title":"Vagus nerve stimulation induces widespread cortical and behavioral activation","volume":"31","author":"Collins","year":"2021","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13229-021-00416-y","article-title":"Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome","volume":"12","author":"Copping","year":"2021","journal-title":"Mol. Autism"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-021-01082-x","article-title":"Emerging gene and small molecule therapies for the neurodevelopmental disorder angelman syndrome","author":"Copping","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/aur.2418","article-title":"CIM6P\/IGF-2 receptor ligands reverse deficits in angelman syndrome model mice","volume":"14","author":"Cruz","year":"2021","journal-title":"Autism Res"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1528-1167.2007.01178_5.x","article-title":"Lamotrigine effect on GABA transmission in Angelman syndrome?","volume":"48","author":"Dan","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13229-018-0214-8","article-title":"Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study","volume":"9","author":"den Bakker","year":"2018","journal-title":"Mol. Autism"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.yebeh.2012.10.033","article-title":"Sleep and epilepsy","volume":"26","author":"Derry","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1528-1167.2006.00969.x","article-title":"Lamotrigine therapy of epilepsy with Angelman\u2019s syndrome","volume":"48","author":"Dion","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajmg.a.61385","article-title":"Behavioral characterization of dup15q syndrome: Toward meaningful endpoints for clinical trials","volume":"182","author":"DiStefano","year":"2020","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib32","first-page":"621","article-title":"The puppet-like syndrome of Angelman","volume":"135","author":"Dooley","year":"1981","journal-title":"Am. J. Dis. Child"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib33","first-page":"1","article-title":"A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome","volume":"10","author":"Duis","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib34","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.1523\/JNEUROSCI.2194-15.2015","article-title":"Maternal Ube3a loss disrupts sleep homeostasis but leaves circadian rhythmicity largely intact","volume":"35","author":"Ehlen","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.nbd.2010.12.001","article-title":"Drosophila Ube3a regulates monoamine synthesis by increasing GTP cyclohydrolase I activity via a non-ubiquitin ligase mechanism","volume":"41","author":"Ferdousy","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.620119","article-title":"Repurposing cholinesterase inhibitors as antidepressants? Dose and stress-sensitivity may be critical to opening possibilities","volume":"14","author":"Fitzgerald","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113323","article-title":"Multiple cholinesterase inhibitors have antidepressant-like properties in the mouse forced swim test","volume":"409","author":"Fitzgerald","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1824-7288-36-31","article-title":"Epilepsy in patients with Angelman syndrome","volume":"36","author":"Fiumara","year":"2010","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopsych.2019.01.008","article-title":"Electrophysiological phenotype in angelman syndrome differs between genotypes","volume":"85","author":"Frohlich","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jnc.12726","article-title":"Reversal of reduced parvalbumin neurons in hippocampus and amygdala of Angelman syndrome model mice by chronic treatment of fluoxetine","volume":"130","author":"Godavarthi","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbrc.2015.07.103","article-title":"Impaired adult hippocampal neurogenesis and its partial reversal by chronic treatment of fluoxetine in a mouse model of Angelman syndrome","volume":"464","author":"Godavarthi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib42","doi-asserted-by":"crossref","DOI":"10.1046\/j.1440-1819.2002.01022.x","article-title":"The neurochemistry of waking and sleeping mental activity:the disinhibition-dopamine hypothesis","author":"Gottesmann","year":"2002","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2016.12.018","article-title":"Low glycemic index treatment for seizure control in Angelman syndrome: a case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital","volume":"68","author":"Grocott","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1172\/JCI120816","article-title":"Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice","volume":"129","author":"Gu","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib45","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1172\/JCI130419","article-title":"Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice","volume":"129","author":"Gu","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3171\/2022.1.PEDS222","article-title":"The role of vagus nerve stimulation in genetic etiologies of drug-resistant epilepsy: a meta-analysis","volume":"29","author":"Hajtovic","year":"2022","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5664\/jcsm.8284","article-title":"Mirtazapine for sleep disturbances in Angelman syndrome: a retrospective chart review of 8 pediatric cases","volume":"16","author":"Hanzlik","year":"2020","journal-title":"J. Clin. Sleep. Med."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bpsgos.2021.05.003","article-title":"Electrophysiological abnormalities in angelman syndrome correlate with symptom severity","volume":"1","author":"Hipp","year":"2021","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"issue":"80","key":"10.1016\/j.eplepsyres.2024.107286_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.1094539","article-title":"Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups","volume":"189","author":"Hobson","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic-adrenergic hypothesis of mania and depression","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","article-title":"Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation","volume":"21","author":"Jiang","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144712","article-title":"Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice","volume":"6","author":"Judson","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.02.040","article-title":"GABaergic neuron-specific loss of Ube3a causes angelman syndrome-like EEG abnormalities and enhances seizure susceptibility","volume":"90","author":"Judson","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib54","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737175.2023.2245568","article-title":"Current and emerging treatment options for Angelman syndrome","volume":"23","author":"Keary","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib55","first-page":"287","article-title":"Angelman syndrome","author":"Kyllerman","year":"2013"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.braindev.2003.09.013","article-title":"Angelman syndrome: Is there a characteristic EEG?","volume":"27","author":"Laan","year":"2005","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1157.1997.tb01097.x","article-title":"Evolution of epilepsy and EEG findings in Angelman syndrome","volume":"38","author":"Laan","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.81892","article-title":"Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome","volume":"12","author":"Lee","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","article-title":"CDKL5 deficiency disorder: clinical features, diagnosis, and management","volume":"21","author":"Leonard","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib60","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/aur.2709","article-title":"Evaluation of electroencephalography biomarkers for Angelman syndrome during overnight sleep","volume":"15","author":"Levin","year":"2022","journal-title":"Autism Res"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib61","first-page":"701","article-title":"Revisiting epilepsy and the electroencephalogram patterns in Angelman syndrome","volume":"35","author":"Leyser","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.devbrainres.2005.03.014","article-title":"GABAA receptor \u03b23 subunit gene-deficient heterozygous mice show parent-of-origin and gender-related differences in \u03b23 subunit levels, EEG, and behavior","volume":"157","author":"Liljelund","year":"2005","journal-title":"Dev. Brain Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2022.1531","article-title":"Two siblings suffering from Angelman Syndrome with a novel c.1146T>G mutation in UBE3A: a case report","volume":"16","author":"Liu","year":"2022","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib64","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1073\/pnas.1504809112","article-title":"Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression","volume":"112","author":"Mandel-Brehm","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2021.1939674","article-title":"Therapies in preclinical and clinical development for Angelman syndrome","volume":"30","author":"Markati","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1550059420973095","article-title":"Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics","volume":"54","author":"Martinez","year":"2023","journal-title":"Clin. EEG Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng0197-74","article-title":"De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome","volume":"15","author":"Matsuura","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/0006-8993(76)90480-7","article-title":"Dorsal raphe neurons: depression of firing during sleep in cats","author":"Mcginty","year":"1976","journal-title":"Brain Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ridd.2016.06.002","article-title":"Epilepsy and cataplexy in Angelman syndrome. Genotype-phenotype correlations","volume":"56","author":"Mertz","year":"2016","journal-title":"Res. Dev. Disabil."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-018-0024-x","article-title":"Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice","author":"Mineur","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib72","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-10-2949","article-title":"Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems","volume":"17","author":"More","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib73","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s13311-022-01239-2","article-title":"Improving gene therapy for angelman syndrome with secreted human UBE3A","volume":"19","author":"Nenninger","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib74","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","article-title":"Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model","volume":"31","author":"O\u2019Geen","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib75","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/acn3.51385","article-title":"Delta power robustly predicts cognitive function in Angelman syndrome","volume":"8","author":"Ostrowski","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000515434","article-title":"Gene Transfer Therapy for Neurodevelopmental Disorders","volume":"43","author":"Ozlu","year":"2021","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib77","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00213-016-4206-0","article-title":"Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats","volume":"233","author":"Papp","year":"2016","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib78","first-page":"577","article-title":"Behavior and neuropsychiatric manifestations in Angelman syndrome","volume":"4","author":"Pelc","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.seizure.2007.08.004","article-title":"Epilepsy in Angelman syndrome","volume":"17","author":"Pelc","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib80","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/ajmg.a.61642","article-title":"Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome","volume":"182","author":"Pereira","year":"2020","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-4939-7774-1_12","article-title":"Purified Protein Delivery to Activate an Epigenetically Silenced Allele in Mouse Brain","volume":"1767","author":"Pyles","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib82","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1172\/JCI61888","article-title":"Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome","volume":"122","author":"Riday","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neuroscience.2020.02.017","article-title":"Angelman syndrome: from mouse models to therapy","volume":"445","author":"Rotaru","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib84","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.0083-18.2018","article-title":"Adult Ube3a gene reinstatement restores the electrophysiological deficits of prefrontal cortex layer 5 neurons in a mouse model of angelman syndrome","volume":"38","author":"Rotaru","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0013-4694(96)96105-2","article-title":"Angelman\u2019s syndrome: clinical and electroencephalographic findings","volume":"102","author":"Rubin","year":"1997","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.braindev.2020.08.014","article-title":"Epilepsy in Angelman syndrome: a scoping review","volume":"43","author":"Samanta","year":"2021","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib87","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/14656566.2022.2105141","article-title":"Pharmacotherapeutic management of seizures in patients with Angleman Syndrome","volume":"23","author":"Samanta","year":"2022","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142574","article-title":"CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice","volume":"131","author":"Schmid","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2016.04.030","article-title":"Seizure treatment in Angelman syndrome: a case series from the Angelman Syndrome Clinic at Massachusetts General Hospital","volume":"60","author":"Shaaya","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib90","first-page":"1","article-title":"5-Hydroxytryptamine 2 receptor facilitates GABAergic neurotransmission in rat","author":"Shen","year":"1998","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib91","first-page":"14","article-title":"Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis","volume":"9","author":"Sidorov","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib92","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1172\/JCI80554","article-title":"Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model","volume":"125","author":"Silva-Santos","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib93","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0925-2312(00)00206-X","article-title":"Reciprocal inhibitory connections produce desynchronizing phase lags during intrathalamic oscillations","author":"Sohal","year":"2000","journal-title":"Neurocomputing"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13229-018-0231-7","article-title":"A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants","volume":"9","author":"Sonzogni","year":"2018","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13229-019-0277-1","article-title":"Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes","volume":"10","author":"Sonzogni","year":"2019","journal-title":"Mol. Autism"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081157","article-title":"Rett syndrome spectrum in monogenic developmentalepileptic encephalopathies and epilepsies: a review","volume":"12","author":"Spagnoli","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/braincomms\/fcac106","article-title":"Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome","volume":"4","author":"Spencer","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib98","article-title":"Monoaminergic mechanisms in epilepsy may offer innovative therapeutic opportunity for monoaminergic multi-target drugs","author":"Strac","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib99","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gr.7.4.368","article-title":"The E6-AP ubiquitin protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region","volume":"7","author":"Sutcliffe","year":"1997","journal-title":"Genome Res"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000542-199609000-00014","article-title":"Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices","volume":"85","author":"Talke","year":"1996","journal-title":"Anesthesiology"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib101","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ajmg.a.38457","article-title":"A randomized controlled trial of levodopa in patients with Angelman syndrome","volume":"176","author":"Tan","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib102","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pediatrneurol.2012.09.015","article-title":"Neurologic manifestations of Angelman syndrome","volume":"48","author":"Thibert","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib103","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1528-1167.2009.02108.x","article-title":"Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options","volume":"50","author":"Thibert","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib104","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1528-1167.2012.03537.x","article-title":"Low glycemic index treatment for seizures in Angelman syndrome","volume":"53","author":"Thibert","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00381-018-3723-z","article-title":"Vagal nerve stimulation for medically refractory epilepsy in Angelman syndrome: a series of three cases","volume":"34","author":"Tomei","year":"2018","journal-title":"Child\u2019s Nerv. Syst."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0006-8993(01)02653-1","article-title":"Effects of ENA713 and CHF2819, two anti-Alzheimer\u2019s disease drugs, on rat amino acid levels","volume":"910","author":"Trabace","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1566523220666200107151025","article-title":"Gene therapy for angelman syndrome: contemporary approaches and future endeavors","volume":"19","author":"Tsagkaris","year":"2020","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib108","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1528-1157.2003.66502.x","article-title":"Angelman syndrome: Difficulties in EEG pattern recognition and possible misinterpretations","volume":"44","author":"Valente","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib109","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nn1845","article-title":"Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of \u03b1CaMKII inhibitory phosphorylation","volume":"10","author":"Van Woerden","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.yebeh.2011.11.027","article-title":"Analysis of EEG patterns and genotypes in patients with Angelman syndrome","volume":"23","author":"Vendrame","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib111","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neuron.2012.03.036","article-title":"Maternal loss of Ube3a produces an excitatory\/inhibitory imbalance through neuron type-specific synaptic defects","volume":"74","author":"Wallace","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib112","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1152\/jn.00618.2016","article-title":"Ube3a loss increases excitability and blunts orientation tuning in the visual cortex of angelman syndrome model mice","volume":"118","author":"Wallace","year":"2017","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.braindev.2003.11.009","article-title":"Electroclinical characteristics of seizures - Comparing Prader-Willi syndrome with Angelman syndrome","volume":"27","author":"Wang","year":"2005","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/tcmj.tcmj_103_19","article-title":"Clinical characteristics and epilepsy in genomic imprinting disorders: angelman syndrome and Prader-Willi syndrome","volume":"32","author":"Wang","year":"2020","journal-title":"Tzu Chi Med. J."},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107286_bib115","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-018-9225-1","article-title":"The first international conference on SYNGAP1-related brain disorders: a stakeholder meeting of families, researchers, clinicians, and regulators","volume":"10","author":"Weldon","year":"2018","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","article-title":"Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA","volume":"587","author":"Wolter","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib117","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/acn3.50848","article-title":"Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome","volume":"6","author":"Wong","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib118","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2018.02.027","article-title":"Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome","volume":"82","author":"Worden","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107286_bib119","article-title":"Dexmedetomidine alleviates postoperative cognitive dysfunction by inhibiting neuron excitation in aged rats","author":"Xiong","year":"2016","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.eplepsyres.2024.107286_bib120","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/jnr.24576","article-title":"Towards an understanding of Angelman syndrome in mice studies","volume":"98","author":"Yang","year":"2020","journal-title":"J. Neurosci. Res."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:17:16Z","timestamp":1736219836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121124000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":120,"alternative-id":["S0920121124000019"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107286","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neural hyperexcitability in Angelman syndrome: Genetic factors and pharmacologic treatment approaches","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107286"}}